pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
fda medwatch·Aug 3·1 min read
save

BD recalls specific lots of intraosseous needle sets over obturator removal issues

Aug 3, 2026·read at fda medwatch ↗CRLNegative

BD announced a voluntary recall of certain lots of its intraosseous vascular access system needle sets after users reported difficulty removing the obturator after placement.

The issue is linked to out-of-tolerance dimensions in the affected lots, which were manufactured between September 30, 2024 and June 12, 2026, and may occur if the drill is not pulled straight back or the obturator is rotated incorrectly during removal.

Clinicians may need to obtain a new IO needle or switch to an alternative vascular access device such as a peripheral IV catheter, which could delay therapy for critically ill patients.

The recall does not impact the BD intraosseous powered driver.

source

This writeup was produced by pharmadog from original reporting by fda medwatch.

Original headline: “BD Issues Nationwide Recall for Specific Lots of BD® Intraosseous Vascular Access System Needle Sets Due to Reports of Difficulty Removing the Obturator”

read at fda medwatch ↗
685 words · retrieved Aug 4
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Recall7

related stories

  • Jul 21Biotech industry leaders file brief backing FDA against ‘malicious’ mifepristone challengeFierce Biotech
  • Jul 21STAT+: Pharmalittle: We’re reading about Novo suing Lilly over ‘deceptive’ ads, a fugitive’s secret life in biotech, and moreSTAT
  • Jul 21A renewed push from the right against abortion pillsSTAT
  • Jul 20FDA still focused on lettuce supplier as source of parasite, despite faulty test resultSTAT
  • Jul 17STAT+: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and moreSTAT